20 July 2021
BDA advises Navis on the sale of majority stake in OPV Pharmaceuticals to RV Healthcare
![](https://www.bdapartners.com/wp-content/uploads/2021/07/opv.png)
a portfolio company of
![](https://www.bdapartners.com/wp-content/uploads/2022/08/Navis-175x175-1.png)
has been acquired majority stake by
![](https://www.bdapartners.com/wp-content/uploads/2021/07/rv-300x69.png)
2021
Recent transactions
divested majority stake in
to
2024
acquired majority stake in
2024
has been acquired by
2023
received investment from
2023
a subsidiary of
has acquired
2022
a portfolio company of
has been acquired by
2022
agreed to divest East Syracuse, New York facility to
2022
has sold minority stake to
2022
a portfolio company of
has been acquired by
2022
investment from
2021
has been acquired by
2021
a portfolio company of
has been acquired by
2021
divested majority stake to
DCP Capital
2021
agreed to divest Couvet, Switzerland facility to WuXi AppTec
2021
raised Series B round from
2021
backed by
has been acquired by
2020
divested Escientia Life Sciences to Deccan Fine Chemicals
2020
divested significant stake in
Kehua Bio-Engineering to Gree Real Estate
2020
majority sale
2019
LAP Lasers a portfolio company of
has been acquired by
2019